Whole Body Health Sale

Abstracts













VERTIGO
(Page 2)


Printing? Use This!
Table of Contents

bar

book [Evaluation of the therapeutic effectiveness of a piracetam plus dihydroergocristine combination in the treatment of vertigo]
book [Treatment of vertigo syndrome with Nootropil]
book The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.
book The balancing outcome of a pharmacological treatment by vertiginous patients.
book Dizziness and dizzy feeling in the elderly: Treatment.
book Disabling acute vertigo attack.
book Vertigo.
book Hemorheologic therapy of vertigo.
book Vertigo, dysarthria and hemiparesis in a 71 year-old woman.
book Drugs for dizziniess; exploitation of medical incapability.
book Vertigo syndrome treatment by nootropil.
book Clinic assay on the assocation piracetam and dihydroergocristine in vertigo of several etiologies.
book Treatment of vertigo with piracetam: Comparison with placebo in 50 cases.
book Current concepts in management.
book The effect of piracetam (Nootropil, UCB 6215) upon the late symptoms of patients with head injuries.
book Piracetam in patients with chronic vertigo. Results of a double-blind,placebo-controlled study
book Nootropics: Efficacy and tolerability of products from three active substance classes
book The effect of ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability
book [Clinical trial of the use of the combination of piracetam and dihydroergocristine in vertigo from different causes]
book Treatment of vertigo syndrome with Nootropil]
book The use of piracetam in vertigo.
book The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.
book Piracetam in the treatment of post-concussional syndrome. A double-blind study.
book [Evaluation of the therapeutic effectiveness of a piracetam plus dihydroergocristine combination in the treatment of vertigo]
book [Hydergine in pathology of the inner ear]
book [The elimination of chemotherapy side effects in pulmonary tuberculosis patients]
book The treatment of minocycline-induced brainstem vertigo by the combined administration of piracetam and ergotoxin.


bar



[Evaluation of the therapeutic effectiveness of a piracetam plus dihydroergocristine combination in the treatment of vertigo]

Lopez Martinez R
Acta Otorrinolaringol Esp (Spain) Jul-Aug 1988, 39 (4) p287-8.

No abstract.



[Treatment of vertigo syndrome with Nootropil]

Miszke A; Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7.

No abstract.



The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.

Oosterveld WJ
Arzneimittelforschung (Germany, West) 1980, 30 (11) p1947-9.

In a double-blind trial according to a switchback design with 4 periods of one week each a comparison was made between the effects of piracetam and a placebo. In 22 patients with vertigo of central origin (posttraumatic, psychogenic, ecileptogenic and hypertensive vertigo were excluded) piracetam was found to significantly reduce symptoms. On anamnestic examination the patients noted the effect of both substances on vertigo, motility disturbances, vitality and sleep. Piracetam was found to have a significant effect on the first three. The effect of piracetam is explained by an enhanced control of the cerebral cortex on the subordinated vestibular centers, in agreement with findings in the literature on animal and human pharmacology.



The balancing outcome of a pharmacological treatment by vertiginous patients

Rocher F.P.
Dr. F.P. Rocher, Rotova 50, 46700 Gandia (Valencia) Spain
Anales Otorrinolaringologicos Ibero-Americanos (Spain) 1999, 26/3 (271-291)

From the age of sixty, vertigo is mainly due to vertebro-basilar insufficiency. It has been described that the association of Dihydroergocristine-Piracetam (D-P) is a usefull treatment for vertebro- basilar insufficiency. That is why we have designed a comparative study between D-P an a Placebo, so that prove if this association can be usefull in the treatment of vertigo occassionated by cerebrovascular insufficiency. Fifty patients complaining of vertigo were included in the study after an untreatment term. 19 received a daily capsule of Placebo, and the other 31, treated with D-P, were divided in two groups: 16 patients received a dose of 3 mg Dihydroergocristine + 1,6 g Piracetam every 12 hours per os; and 15 other were treated with 1,5 mg Dihydroergocristine + 0,8 g Piracetam every 8 hours during 90 days. The patients were evaluated at the beginning of the study and 90 days later, with anamnesis and vestibular tests. In the last consultation the patients autoevaluated themselves the effect and the tolerance to the drugs received. In the Placebo group it was observed an improvement or disappearance of vertiginous symptoms in the 68,5% of the cases, while with D-P was 93,7% at the dose of 3 mg Dihydroergocristine + 1,6 Piracetam each 12 hours and 100% with the dose 1,5 mg Dihydroergocristine + 0,8 Piracetam each 8 hours. None of the treated patients with D-P worsened their symptoms. We observe a considerable decrease in the number of patients with vegetative symptoms in the group treated with D-P related to the Placebo group, though the symptoms persisted more time in the group treated with D-P that in the Placebo group. The group treated with D-P get a higher percentage of improvements and disappearance of auditive and cervical symptoms that the group treated with Placebo. In the vestibulo-spinal and cerebellous tests it was observed a better improvement with D-P at the dose of 1,5 mg of Dihydroergocristine + 0,8 g Piracetam each hours compared with the other two groups. It can be concluded that the association D-P is an effective treatment for vertigo, getting also a higher normalization of the vestibular tests than Placebo.



Dizziness and dizzy feeling in the elderly: Treatment

Marquet T.; Belmin J.
J. Belmin, Serv. Medecine Interne Geriatrique, Hopital Rene Muret-Bigottini, 93720 Sevran France
Revue de Geriatrie (France) 1997, 22/7 (457-462)

No abstract.



Disabling acute vertigo attack

Moussalle S.
Servicio de Otorrinolaringologia, Faculdade de Medicina, Pontificia Universidade Catolica,Rio Grande Do Sul Brazil
Revista Brasileira de Otorrinolaringologia (Brazil) 1994, 60/4 (326)

No abstract.



Vertigo

Gananca M.M.; Caovilla H.H.; Gananca F.F.; De Toledo Piza Peluso E.
Rua Dr. A. de Campos Rodrigues, 309,CEP 04544-000, Sao Paulo Brazil
Revista Brasileira de Medicina (Brazil) 1993/1994, 50/Spec. Iss. Dec. (193-202)

The importance of the neurootological evaluation was justified in order to establish the adequate diagnosis for the adequate therapy. Very good results can be obtained in the treatment of vertigo by the use of drugs, rehabilitation exercises and nutritional diets. Surgery is indicated in some particular cases.



Hemorheologic therapy of vertigo

Spurk P.; Dehnert H.G.; Angelkort B.
St. Vincenzkrankenhaus, D-5750 Menden 1 Germany
Vasa - Journal of Vascular Diseases (Switzerland) 1991, 20/Suppl. 33 (169-170)

Hemorheological treatment in vertigo. Depending on data of hemorheology disturbances in risk factors and carotid artery artherosclerosis-progression in vertigo on non-vestibular origin this study evaluates treatment effects by basis, i.e. correction of risk factors only, versus additional hemorheological treatment (Lowering hct., HAES, Pentoxifylline). Patients: N = 88 fe.51 m 37 age 25-86 mean 65.1. Results: ++ base gr. 35% hemorh. 62% + base gr. 40% hem. 38% no effect base gr. 25% hemorh. none.



Vertigo, dysarthria and hemiparesis in a 71 year-old woman

Vespignani H.; Defer G.; Gray F.
Service de Neurologie, Nancy France
Revue Neurologique (France) 1991, 147/11 (752-758)

No abstract.



Drugs for dizziniess; exploitation of medical incapability

Van Gijn J.
Vakgroep Neurologie, Academisch Ziekenhuis, Postbus 85500, 3508 GA Utrecht Netherlands
Nederlands Tijdschrift voor Geneeskunde (Netherlands) 1991, 135/14 (599-603)

No abstract.



Vertigo syndrome treatment by nootropil

Miszke A.; Rapacz K.
Oddzial Otolaryngologiczny KSZ im G. Narutowicza, Krakow Poland
Otolaryngologia Polska (Poland) 1988, 42/5 (312-317)

No abstract.



Clinic assay on the assocation piracetam and dihydroergocristine in vertigo of several etiologies

Ordosgoitia H.; Castro C.; Carbayeda M.; Labella T.
Facultad de Medicina, Catedra de O.R.L., 15704 Santiago de Compostela Spain
Anales Otorrinolaringologicos Ibero-Americanos (Spain) 1989, 16/3 (271-279)

No abstract.



Treatment of vertigo with piracetam: Comparison with placebo in 50 cases

Haguenauer J.-P.
Gazette Medicale (France) 1986, 93/28 (67-70)

No abstract.



Current concepts in management

Oosterveld W.J.
Vestibular Department, Ear, Nose and Throat Clinic, Academisch Medisch Centrum, Amsterdam Netherlands
Drugs (Australia) 1985, 30/3 (275-283)

Vertigo is not a disease, but a symptom. The management of vertigo requires more than the treatment of the symptom alone, as it concerns the whole physical and psychological condition of the patient. In addition to causal treatment, symptomatic treatment is needed in many cases. This specific treatment consists of vestibular exercises and drug therapy. The efficacy and use of the different drugs available are discussed.



The effect of piracetam (Nootropil, UCB 6215) upon the late symptoms of patients with head injuries

Aantaa E.; Meurman O.H.
Otolaryngol. Univ. Clin., Turku Finland
Journal of International Medical Research 1975, 3/5 (352-355)

Sixty patients whose head injuries had occurred 2-6 mth previously were examined in a double blind trial to demonstrate the effect of piracetam (UCB 6215) upon late symptoms. A significantly better result of treatment of vertigo was established in the piracetam group compared to the placebo group. The disappearance of symptoms of vertigo could also be objectively established by diminished spontaneous and positional nystagmus as well as diminished pendel deviations with eyes closed. No significant change during the period of treatment could be established with respect to the caloric test.



Piracetam in patients with chronic vertigo. Results of a double-blind,placebo-controlled study

Rosenhall U.; Deberdt W.; Friberg U.; Kerr A.; Oosterveld W.
UCB Pharma, International Development, Chemin du Foriest, B-1420 Braine-l'Alleud Belgium
Clinical Drug Investigation (New Zealand), 1996, 11/5 (251-260)

The nootropic agent piracetam, which exerts diverse effects through actions on cerebral neurotr reported to alleviate vertigo. We performed a multicentre, double-blind, placebo-controlled study to assess the efficacy and tolerability of piracetam 800 mg 3 times daily orally for 8 weeks. The study group consisted of 143 middle-aged and elderly outpatients of ear, nose and throat clinics who had suffered from vertigo for at least 3 months, had experienced at least 3 episodes per month, and the vertigo was severe enough to disrupt daily life. Primary outcome measures were patient self-evaluations of vertigo: the frequency of episodes, and their severity using visual analogue scales (VAS). Malaise and imbalance between episodes (VAS), the effect of vertigo on walking (VAS), the duration of incapacity, and overall evaluations by patients and investigators were also assessed. On entry, episodes were more frequent (p< 0.05) and malaise between episodes more severe (p < 0.05) in the piracetam group. Data were not evaluable in 54 patients because of either adverse events (12 piracetam, 12 placebo) or protocol deviations. An intention-to-treat analysis showed that episodes of vertigo were less frequent (p < 0.03) but not less severe on piracetam than on placebo: interval malaise (p < 0.05) and imbalance (p < 0.01) improved more and the duration of incapacity was less (p < 0.05). These changes, which were maximal after 8 weeks' medication, had almost disappeared 4 weeks after the end of treatment. Tolerance to piracetam was good, with few drug-related adverse events occurring. These findings provide further evidence that piracetam alleviates vertigo by reducing the frequency of episodes, the severity of malaise and imbalance between episodes, and the duration of associated incapacity.



Nootropics: Efficacy and tolerability of products from three active substance classes

Letzel H.; Haan J.; Feil W.B.
STATICON Medizinische, Forschunsgesellschaft mbH, Behringstrasse 12, D-82152 Planegg Germany
Journal of Drug Development and Clinical Practice (United Kingdom), 1996, 8/2 (77-94)

This paper reviews and evaluates all the currently available clinical trials on the efficacy of three nootropics. Only randomised, double-blind, placebo-controlled clinical trials were taken into account which produced 44 studies allowing comparison of the patient populations, efficacy and tolerability of Ginkgo biloba special extracts, nimodipine and tacrine. Taking all the studies together, statistically significant results were obtained at three relevant levels of efficacy (psychopathological, psychometric, behavioural) for all three substances. Nine studies produced significant results at all three efficacy levels. One study on Ginkgo biloba and one on tacrine also produced significant rerationalised diagnosis of dementia, inclusion of mild-to-moderate cases, statistical proof at all three levels of efficacy and global clinical evaluation). The clinical efficacy of all three substances has thus been demonstrated.



The effect of ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability

Erdincler D.S.; Karakoc Y.; Toplan S.; Onen S.; Sukyasyan A.; Beger T.; Demiroglu C.
Gerontology Division, Department of Internal Medicine, I.U. Cerrahpasa Medical Faculty, Istanbul Turkey
Clinical Hemorheology (USA), 1996, 16/3 (271-276)

In this study, we investigated the effect of ginkgoglycoside in two different doses (19.2 mg/day and 28.8 mg/day) on blood viscosity and erythrocyte deformability in 27 patients suffering from cerebrovascular insufficiency. The patients were divided into two groups randomly consisting of 13 and 14 patients respectively. Both groups received 28.8 mg/day ginkgoglycoside between the 1st and 15th day. The first group received the same dose until the end of the 30th day, whereas the dose administrated to the second group was reduced to 19.2 mg/day. In the first group, during 30 days a significant decrease in blood viscosity and a significant increase in erythrocyte deformability were observed. In the second group on the other hand, after dose reduction, the effect of the drug on blood viscosity and erythrocyte deformability were diminished. Improvement of symptoms including vertigo, tinnutus, headache and forgetfulness in the first group was found to be significantly different from the 2nd group at day 30 in a dose dependent manner.



[Clinical trial of the use of the combination of piracetam and dihydroergocristine in vertigo from different causes]

Ordosgoitia H, Castro C, Carbayeda M, Labella T
An Otorrinolaringol Ibero Am. 1989;16(3):271-9

We report on the therapeutic effect of a combination of piracetam and dihydroergocristine in 55 vertiginous patients, of both sexes, between 20 and 67 years of age, from different causes (not scheduled for surgery). The trial lasted 3 months, and the drugs were taken twice daily. Aside from one case who stopped the drug therapy because of intolerance, the conclusions drawn by the AA. are seemingly good, both subjectively and objectively (audiometric and electronystagmographic tracings).



[Treatment of vertigo syndrome with Nootropil]

Miszke A, Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7

No abstract.



The use of piracetam in vertigo.

Fernandes CM; Samuel J
S Afr Med J (South Africa) Nov 23 1985, 68 (11) p806-8

A pilot study with piracetam (Nootropil; UCB) was performed in 5 selected dizzy patients who had a diagnosis of presbyvertigo or vertebrobasilar insufficiency. The study was monitored by assessing the effect of piracetam on the pursuit-tracking system. All patients showed a remarkable improvement in their pursuit tracking, in addition to marked subjective improvement in their vertigo.



The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.

Oosterveld WJ.
Arzneimittelforschung. 1980;30(11):1947-9.

In a double-blind trial according to a switchback design with 4 periods of one week each a comparison was made between the effects of piracetam and a placebo. In 22 patients with vertigo of central origin (posttraumatic, psychogenic, ecileptogenic and hypertensive vertigo were excluded) piracetam was found to significantly reduce symptoms. On anamnestic examination the patients noted the effect of both substances on vertigo, motility disturbances, vitality and sleep. Piracetam was found to have a significant effect on the first three. The effect of piracetam is explained by an enhanced control of the cerebral cortex on the subordinated vestibular centers, in agreement with findings in the literature on animal and human pharmacology.



Piracetam in the treatment of post-concussional syndrome. A double-blind study.

Hakkarainen H; Hakamies L
Eur Neurol (Switzerland) 1978, 17 (1) p50-5

The effect of piracetam, a cyclical derivative of GABA, was compared with that of a placebo in a double-blind study of 60 patients with post-concussional syndrome of 2-12 months' duration. The daily dose of piracetam was 4,800 mg. After 8 weeks of treatment piracetam significantly reduced the occurrence and severity of the following symptoms: vertigo, headache, tiredness, decresed alertness, increased sweating and neurasthenic symptoms. No significant effect was observed on the following symptoms: tremor, orthostatic symptoms, and memory disorders. Side effect were reported by 64% of the patients under piracetam and by 32% under placebo. In the author's opinion, piracetam seems to be a promising new drug for the treatment of post-concussional syndrome.



[Evaluation of the therapeutic effectiveness of a piracetam plus dihydroergocristine combination in the treatment of vertigo]

Lopez Martinez R.
Acta Otorrinolaringol Esp. 1988 Jul-Aug;39(4):287-8.

No abstract.



[Hydergine in pathology of the inner ear]

Jimenez-Cervantes Nicolas J, Amoros Rodriguez LM
An Otorrinolaringol Ibero Am (1990) 17(1):85-98

There have been treated a total of 20 patients with troubles on the cochlear compartment and/or vestibular level which have been clinically expressed by a perceptive hypoacusia, tinnitus and rotatory vertigo. The final evaluation is referred to 17 patients, since three patients do not appear for control. All patients were treated only with Hydergine, on doses of 30 drops thrice daily, which is the equivalent to 4.5 mg/day of active substance. This treatment remained unaltered till the end of the last control. Controls have been effected after 30, 60 and 90 days of starting the treatment. In each control there was evaluated the subjective improvement of vertigo, tinnitus and hypoacusia when effecting to all patients by means of liminar- supraliminar- and automaticaudiometry, impedancimetry, T one-decay-test and electrooculonistagmography. The most meliorated symptomatology was vertigo, with a global improvement of 93.7 per cent on the treated patients. Tinnitus improve by 57.1 per cent and hypoacusia by 20 per cent. There is a total correspondence between the subjective data furnished by the patients and the objective tests carried out in the successive controls.



[The elimination of chemotherapy side effects in pulmonary tuberculosis patients]

Bal'tseva LB; Mel'nik GV; Man'ko VP
Vrach Delo (USSR) Apr 1990, (4) p71-3

Neurotoxic side-effects of tuberculosis chemotherapy occurred in 14.9% of patients with tuberculosis treated prophylactically with intramuscular pyridoxine infusions. Use of small doses of nootropil (piracetam) allowed to control the side-effects (headache and vertigo, sleep disorders, irritation, memory disorders) and to continue treatment with isoniazide, one of the most potent tuberculostatic agents.



The treatment of minocycline-induced brainstem vertigo by the combined administration of piracetam and ergotoxin.

Claussen CF, Schneider D, Patil NP
Acta Otolaryngol Suppl (Stockh). 1989;468:171-4.

Two randomized studies to test the efficacy of a combination of Piracetam and Ergotoxin on the destabilized brainstem are reported. In the first study, a pharmacological model using Minocycline is employed. A follow-up clinical study analysed the effect of the preparation in 5 patients suffering from vertigo and other related complaints. It was seen that there was a significant improvement in the nystagmus profiles of the pharmacological model volunteers. Similarly, the patient group showed a marked improvement in symptoms, and in orientation capability as tested by Cranio-Corpo-Graphy.